No, mupirocin ointment should NOT be used on all types of wounds
Mupirocin is specifically indicated for superficial skin infections caused by Staphylococcus aureus and Streptococcus species, particularly impetigo, and should be avoided in clean surgical wounds and wounds where large polyethylene glycol absorption is possible.
Appropriate Uses
Mupirocin is highly effective and appropriate for:
Impetigo and ecthyma - IDSA guidelines explicitly recommend topical mupirocin as equally effective as oral antimicrobials for impetigo 1. The FDA label confirms application three times daily to affected areas 2.
Superficial infected wounds - Recent evidence shows 99.2% therapeutic response in superficial traumatic and surgical wounds infected with S. aureus and/or S. pyogenes 3. Mupirocin effectively treats secondarily infected dermatoses with significant pathogen eradication 4.
MRSA burn wound infections - Effective for burns covering <20% total body surface area, with complete MRSA elimination within 4 days 5. However, use should be limited to 5 days maximum in this setting.
Critical Contraindications and Limitations
Clean surgical wounds: A randomized trial of 1,801 surgical wounds demonstrated that mupirocin provided no benefit over no ointment for clean surgical wounds (infection rate 2.3% vs 1.4%, P=0.490), and actually risks promoting antibiotic resistance 6. This is explicitly not indicated.
Renal impairment: The polyethylene glycol base can be absorbed from open wounds and is renally excreted. Avoid in moderate-to-severe renal impairment where large quantities could be absorbed 2.
Mucosal surfaces: Not formulated for mucosal use; intranasal formulations exist separately 2.
Large or deep wounds: Safety and efficacy not established for extensive wounds (>20% body surface area in burns) 5.
Common Pitfalls to Avoid
Prolonged use: Limit to 3-5 days for impetigo 2; re-evaluate if no clinical response. Extended use promotes resistance and fungal overgrowth 2.
Resistance concerns: High-level mupirocin resistance in MRSA reaches 11.93% in some regions 7, emphasizing the need for judicious use only when specifically indicated.
Systemic infections: For patients with SIRS, extensive lesions, or carbuncles/abscesses, systemic antibiotics active against MRSA are required as adjuncts to incision and drainage 1. Topical therapy alone is insufficient.
Practical Algorithm
- Identify wound type: Superficial infected (impetigo, folliculitis, secondarily infected dermatoses) → mupirocin appropriate
- Clean surgical wound → do NOT use mupirocin 6
- Check renal function: Moderate-severe impairment with large wound → avoid 2
- Assess extent: >20% BSA burns or deep wounds → insufficient evidence, consider alternatives 5
- Culture if possible: Confirm S. aureus/Streptococcus; if other pathogens, mupirocin ineffective 1
- Duration: Maximum 5-10 days; stop if no response by day 3-5 2
The key distinction is between infected superficial wounds (where mupirocin excels) versus clean surgical wounds or extensive/deep wounds (where it provides no benefit and risks resistance).